| Eligibility |
Inclusion Criteria:
1. Must be aged 18-49 years old (inclusive) at the time of vaccination.
2. Must be able to provide written informed consent.
3. Must have a body mass index (BMI) >/= 18.5 and < 35.0 kg/m2
4. Must be in good health based on physical examination, vital signs*, medical history,
safety labs** (as applicable to the rectal biopsy and no biopsy cohorts) and the
investigator's clinical judgment.
*Vital signs must be within the normal ranges. If a subject has elevated systolic or
diastolic blood pressure, subject may rest for 10 minutes in a quiet room and the
blood pressure may be retaken.
**Safety labs must be within the normal ranges and the normal ranges will be those
used by the reference clinical lab.
5. For female subjects only: If a female participant is of childbearing potential*, she
must use contraception** from 30 days before study product administration through the
end of study participation.
*A woman is considered of childbearing potential unless post-menopausal (defined as
history of >/= 1 year of spontaneous amenorrhea), or permanently surgically sterilized
(bilateral oophorectomy, salpingectomy, hysterectomy).
**Acceptable methods of contraception include: abstinence or no sex with a male,
monogamous relationship with a man who had a vasectomy at least 6 months before the
1st study vaccine, prescription oral contraceptives, intrauterine device (IUD), birth
control implants or injections, contraceptive patch, vaginal ring, condoms and
diaphragms/cervical cap with spermicide ("double barrier" method).
6. Must be available and willing to participate for the duration of this trial.
7. Willing to provide mucosal samples: vaginal secretions for women and oropharyngeal and
rectal secretions for men and women.
8. For the rectal biopsy cohort only, willing to provide rectal biopsies.
Exclusion Criteria:
1. Has ever been diagnosed with meningococcal infection or gonococcal infection at any
anatomic site.
2. Has ever received any serogroup B meningococcal vaccine.
3. Any positive test result for STI (including Neisseria gonorrhoeae (GC) Chlamydia
trachomatis (CT), Rapid Plasma Reagin (RPR) and Human Immunodeficiency Virus (HIV)) at
screening*.
*Female subjects will also be tested for Trichomonas at screening.
4. Any history of Chlamydia trachomatis or syphilis infection at any body site in the
preceding 12 months
5. Has known allergy or history of anaphylaxis or other serious adverse reaction to a
vaccine or vaccine products.
6. Has severe allergy or anaphylaxis to latex.
7. Has an acute illness or temperature >/= 38.0 degrees Celsius on Day 1*.
*Subjects with fever or acute illness on the day of vaccination may be re-assessed and
enrolled if healthy or only minor residual symptoms remain within 3 days.
8. Has a history of a bleeding disorder, or is taking chronic anti-coagulant (e.g.
warfarin, direct thrombin inhibitors, heparin products, etc.), anti-platelet, or
non-steroidal anti-inflammatory drugs (NSAID) therapy.
9. Has history of autoimmune disease, or clinically significant cardiac, pulmonary,
gastrointestinal, hepatic, rheumatologic, or renal disease by history or physical
examination.
10. Has history of active malignancy other than squamous cell or basal cell skin cancer,
unless there has been surgical excision that is considered to have achieved cure*.
*Subjects with a history of skin cancer must not be vaccinated at the previous tumor
site.
11. Has known or suspected congenital or acquired immunodeficiency, or recent history or
current use of immunosuppressive therapy*.
*Anti-cancer chemotherapy or radiation therapy within the preceding 3 years, or
long-term (>/= 2 weeks within the previous 3 months) systemic corticosteroid therapy
(at a dosage of >/= 0.5 mg/kg/day). Intranasal or topical prednisone (or equivalent)
are allowed.
12. Is post-organ and/or stem cell transplant, whether or not on chronic immunosuppressive
therapy.
13. Had major surgery (per the investigator's judgment) within 4 weeks before study entry
or planned major surgery during this trial.
14. Has history of diabetes* mellitus type 1 or type 2, including cases controlled with
diet alone*.
*History of isolated gestational diabetes is not an exclusion criterion.
15. Received live attenuated vaccines from 30 days before first vaccination until 30 days
after second vaccination.
16. Received killed or inactivated vaccines* from 14 days before first vaccination until
14 days after second vaccination.
*For inactivated influenza vaccine, from 7 days before either vaccination until 7 days
after either vaccination.
17. Received mRNA, viral vector, or any other technology platform Corona Virus Disease-19
(COVID-19) vaccine within 14 days prior to first dose of the study product.*
*COVID-19 vaccination should take priority over administration of the study product.
18. Received experimental therapeutic agents within 12 months before first vaccination or
plans to receive any experimental therapeutic agents during this trial except for
Emergency Use Authorization (EUA) COVID-19 therapy.*
*Only exclusionary if, in the opinion of the investigator, they would interfere with
safety or endpoint assessment.
19. Is currently participating or plans to participate in another clinical study which
would involve receipt of an investigational product or undergoing a procedure*.
*Only exclusionary if, in the opinion of the investigator, they would interfere with
safety or endpoint assessment.
20. Received blood products or immunoglobulin in the 3 months before study entry or
planned use during this trial.
21. Has major psychiatric illness in the past 12 months that in the opinion of the
investigator would preclude participation.
22. Has current alcohol use or current or past abuse of recreational or narcotic drugs by
history as judged by the investigator to potentially interfere with study adherence.
23. In the opinion of the investigator cannot communicate reliably, is unlikely to adhere
to the requirements of this trial, or has any condition which would limit the ability
to complete this trial.
24. Is pregnant or breast feeding.
|
